Setmelanotide + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypothalamic Obesity
Conditions
Hypothalamic Obesity
Trial Timeline
Apr 26, 2023 → Apr 16, 2027
NCT ID
NCT05774756About Setmelanotide + Placebo
Setmelanotide + Placebo is a phase 3 stage product being developed by Rhythm Pharmaceuticals for Hypothalamic Obesity. The current trial status is active. This product is registered under clinical trial identifier NCT05774756. Target conditions include Hypothalamic Obesity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06760546 | Phase 3 | Recruiting |
| NCT05774756 | Phase 3 | Active |
| NCT05093634 | Phase 3 | Active |
| NCT04963231 | Phase 2 | Completed |
| NCT03746522 | Phase 3 | Completed |
| NCT03287960 | Phase 3 | Completed |
| NCT02896192 | Phase 3 | Completed |
| NCT02311673 | Phase 2 | Completed |
| NCT02041195 | Phase 1/2 | Completed |
| NCT01749137 | Phase 2 | Completed |
Competing Products
7 competing products in Hypothalamic Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Octreotide | Novartis | Approved | 85 |
| Mibavademab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718 | Rhythm Pharmaceuticals | Phase 1/2 | 38 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide | Rhythm Pharmaceuticals | Phase 2 | 49 |
| Bivamelagon | Rhythm Pharmaceuticals | Phase 2 | 49 |
| LB54640 + Placebo | Rhythm Pharmaceuticals | Phase 2 | 49 |